INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

Please see below for Important Safety Information for EPCLUSA.

EASY ONE-PILL DAILY REGIMEN1

EPCLUSA (SOFOSBUVIR/​VELPATASVIR) DOSING FOR ADULT PATIENTS (NC/CC)1

Pill-icon
One pill, once a day, for 12 weeks1
Pill bottle with pill icon
The fewest number of pills (84 pills)1,2,a
Knife and fork icon
No food requirement
Can be taken with or without food1

aAmong first-line pangenotypic regimens.1,2

DOSING FOR PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER IS BASED ON WEIGHT1

  • Lower-dose formulations are recommended for certain pediatric patients
  • In pediatric patients less than 6 years of age, administer the oral pellets with food to increase tolerability related to palatability

See EPCLUSA full Prescribing Information or Package Insert, including Instructions for Use for oral pellets, for details on dosing for pediatric patients.